Yamamoto Sosuke, Aoyama Toru, Maezawa Yukio, Hashimoto Itaru, Esashi Ryuki, Kazama Keisuke, Uchiyama Mamoru, Numata Koji, Hu Mihwa, Fukuda Momoko, Shimada Kiyoko, Tamagawa Ayako, Saito Aya, Norio Yukawa
Department of Surgery, Yokohama City University, Yokohama, Japan.
Cancer Diagn Progn. 2025 May 3;5(3):353-362. doi: 10.21873/cdp.10447. eCollection 2025 May-Jun.
BACKGROUND/AIM: Lymphocyte-to-C-reactive protein ratio (LCR) is a useful biomarker for predicting the prognosis of various cancers. This study examined the effect of LCR on the oncological prognosis of patients with gastric cancer who underwent curative resection at our institution and considered the mechanisms involved.
In this retrospective cohort study, 258 subjects were selected from the medical records of patients who underwent curative resection for gastric cancer at Yokohama City University between 2005 and 2020. The LCR was calculated using the following formula: LCR=lymphocyte count (number/μl)/C-reactive protein (mg/dl).
The cutoff value for LCR was set at 9,000, and 258 patients were classified into the LCR-low (<9,000) (58 patients) and LCR-high (>9,000) (200 patients) groups. The overall survival (OS) and recurrence-free survival (RFS) rates of the two groups were compared. The 5-year overall survival rate was 54.2% in the LCR-low group and 75.2% in the LCR-high group (p<0.001), and a multivariate analysis showed that it was a useful prognostic factor [hazard ratio (HR)=1.744, 95% confidence interval (CI)=1.009-3.014, p=0.046]. In addition, with regard to RFS, there was a significant difference in the 5-year RFS between the LCR-low group (50.4%) and the LCR-high group (72.3%) (p<0.001). Regarding the comparison of the postoperative clinical course between the two groups, the peritoneal recurrence rate was 24.1% in the LCR-low group and 7.5% in the LCR-high group (p<0.001).
Preoperative LCR is a useful prognostic factor for predicting the oncological prognosis of patients with gastric cancer undergoing curative resection. Thus, the LCR may be a useful tool for the treatment and perioperative management of patients with gastric cancer.
背景/目的：淋巴细胞与C反应蛋白比值（LCR）是预测多种癌症预后的有用生物标志物。本研究探讨了LCR对在我院接受根治性切除的胃癌患者肿瘤学预后的影响，并分析了其中涉及的机制。
在这项回顾性队列研究中，从2005年至2020年在横滨市立大学接受胃癌根治性切除的患者病历中选取了258名受试者。LCR采用以下公式计算：LCR = 淋巴细胞计数（个/μl）/C反应蛋白（mg/dl）。
LCR的临界值设定为9000，258例患者被分为LCR低（<9000）组（58例）和LCR高（>9000）组（200例）。比较两组的总生存期（OS）和无复发生存期（RFS）率。LCR低组的5年总生存率为54.2%，LCR高组为75.2%（p<0.001），多因素分析显示其为有用的预后因素[风险比（HR）=1.744，95%置信区间（CI）=1.009 - 3.014，p = 0.046]。此外，关于RFS，LCR低组（50.4%）和LCR高组（72.3%）的5年RFS存在显著差异（p<0.001）。关于两组术后临床病程的比较，LCR低组的腹膜复发率为24.1%，LCR高组为7.5%（p<0.001）。
术前LCR是预测接受根治性切除的胃癌患者肿瘤学预后的有用预后因素。因此.LCR可能是胃癌患者治疗和围手术期管理的有用工具。
